Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : OPKO Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Entera Bio Reports Data for Oral GLP-2 Peptide Tablet in Short Bowel Syndrome
Details : Entera Bio & Opko Health are developing the first GLP-2 peptide tablet alternative for short bowel syndrome and mucosal inflammation disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : OPKO Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX002
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The poster presentation details a phage therapy panel, comprised of phage directed against Klebsiella pneumoniae, showing a broad target host range and the potential to address carbapenem-resistant and extended spectrum beta-lactamase (ESBL)-producing ba...
Product Name : BX002
Product Type : Microorganism
Upfront Cash : Inapplicable
October 21, 2020
Lead Product(s) : BX002
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable